Anesth Analg 2002;94:1042
© 2002 International Anesthesia Research Society
LETTERS TO THE EDITOR
Propofol Formulation and Pain on Injection
Paul F. White, PhD, MD, FANZCA
Professor and Holder of the Margaret Milam McDermott Distinguished Chair in Anesthesiology, Department of Anesthesiology & Pain Management, University of Texas Southwestern Medical Center at Dallas, Dallas, TX
To the Editor: In the recently published brief report by Rau et al. (1), the investigators described the effect of a "new" emulsion formulation of propofol on the severity of pain on IV injection when compared to Diprivan® (AstraZeneca, Wilmington, DE). Unfortunately, these authors failed to acknowledge a report by Shao et al. (2) which demonstrated that generic formulation of propofol containing a different preservative (sodium meta-bisulfite) (Baxter, Chicago, IL) was also associated with less severe pain on injection than the EDTA-containing Diprivan formulation. It is important to perform a care-ful review of the published literature on a given topic to properly acknowledge the relevant work of others in the field.
References
-
Rau J, Roizen MF, Doenicke AW, et al. Propofol in an emulsion of long- and medium-chain triglycerides: the effect on pain. Anesth Analg 2001; 93: 3824.[Abstract/Free Full Text]
-
Shao X, Li H, White PF, et al. Bisulfite-containing propofol: is it a cost-effective alternative to Diprivan for induction of anesthesia? Anesth Analg 2000; 91: 8715.[Abstract/Free Full Text]
|